Chronic Hepatitis B Virus - Epidemiology Forecast to 2030

Chronic Hepatitis B Virus - Epidemiology Forecast to 2030

  • October 2020 •
  • 125 pages •
  • Report ID: 6025285 •
  • Format: PDF
‘Chronic Hepatitis B Virus (CHB) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CHB epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Chronic Hepatitis B Virus (CHB) Understanding

Chronic Hepatitis B Virus Overview
Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.
HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1–2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).
The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in color, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterward.

Chronic Hepatitis B Virus Diagnosis
This condition is diagnosed with blood tests, which are also used to monitor its effects on the liver. For chronic cases, a liver biopsy may be needed. A biopsy is the removal of a sample of liver tissue for testing.
Screening for HBV involves a simple and relatively low-cost blood test to detect the presence of hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs) in serum. Patients who are HBsAg-negative and do not have antibodies are given the hepatitis B vaccine. Those who are HBsAg-negative and have detectable anti-HBs are already immune (generally from prior vaccination or recovery from an acute infection) and do not require further intervention or testing. A patient who tests positive for HBsAg has an active HBV infection, and further testing is needed to determine the phase of disease and course of action. Recommended initial follow-up testing includes serum ALT and HBV DNA levels, as well as serology for hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). Individuals with chronic HBV infection have circulating HBsAg persistently present in their serum for more than 6 months (without developing anti-HBs).
The hepatitis B virus specifically attacks the liver, so health care providers order blood tests to monitor the health of the liver. Some of the most common liver-related blood tests are described below.
These blood tests measure potential liver damage (or liver inflammation). If a person is infected with the hepatitis B virus, the liver cells can be injured by the virus, and then the liver enzymes can leak into the bloodstream. The higher the number, the greater the risk of potential liver damage.

Epidemiology Perspective
The CHB epidemiology division provides the insights about historical and current CHB patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2017, the total prevalent cases of CHB was 5,797,240 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted CHB epidemiology segmented as [Total Prevalent Cases of CHB, Diagnosed cases of CHB, Gender-specific cases of CHB, Diagnosed cases of CHB by Age Distribution, Diagnosed cases of CHB by Impact on Liver, and Treated cases of CHB] scenario of CHB in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- CHB Epidemiology
Estimates show that the highest prevalent cases of CHB in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.
• The United States, in 2017, accounted for 2,276,030 CHB prevalent cases, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in EU5 were 2,231,406, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in Japan were 1,289,804, which are expected to grow during the study period, i.e., 2017–2030.

Country Wise- CHB Epidemiology
Estimates show that the highest prevalent cases of CHB in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.
• The United States, in 2017, accounted for 2,276,030 CHB prevalent cases, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in EU5 were 2,231,406, which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of CHB in Japan were 1,289,804, which are expected to grow during the study period, i.e., 2017–2030.

Scope of the Report
• The CHB report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The CHB Report and Model provide an overview of the risk factors and global trends of CHB in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of CHB in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of CHB.
• The report provides the segmentation of the CHB epidemiology by prevalent cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by diagnosed cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by gender-specific cases in the 7MM.
• The report provides the segmentation of the CHB epidemiology by age distribution in the 7MM.
• The report provides the segmentation of the diagnosed cases of CHB epidemiology by Impact on Liver in the 7MM.
• The report provides the segmentation of the CHB epidemiology by treated cases of CHB in the 7MM.

Report Highlights

• 11-Year Forecast of CHB epidemiology
• 7MM Coverage
• Total Prevalent Cases of CHB
• Total Diagnosed Cases of CHB
• Gender-Specific Cases of CHB
• Age distribution Cases of CHB
• Diagnosed Cases of CHB by impact on liver
• Treated cases of CHB
KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
• What are the key findings pertaining to the CHB epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of CHB across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of CHB?

Reasons to buy
The CHB Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global CHB market
• Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for CHB therapeutics in each of the markets covered
• Understand the magnitude of CHB population by its severity
• The CHB epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The CHB Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
• The United States, in 2017, accounted for 773,850 diagnosed prevalent cases (approximately 47% of the 7MM diagnosed prevalent cases), which will probably rise during the study period, i.e., 2017–2030.
• In the 7MM, the total gender-specific diagnosed prevalent cases of CHB were 956,533 for males and 675,997 for females in the year 2017.
• In the 7MM, the Age-specific Diagnosed Prevalent Cases of CHB were 48,774, 417,880, 385,462, 410,357, 294,578, and 75,479 cases for the age group less than 18 years, 18–34 years, 35–44 years, 45–54 years, 55–64 years, and ?65 years, in 2017.